97302 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Internalization into the cell
Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
#902HER1 ANTIGEN BINDING PROTEINS BINDING TO THE BETA-HAIRPIN OF HER1
#903PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
#904ANTI-PTK7 ANTIBODY-DRUG CONJUGATES
#905Anti-TROP2 antibody-drug conjugate
#906Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides
#907Antagonist antibodies to human prolactin receptor (PRLR)
#908HER3 antigen binding proteins binding to the beta-hairpin of HER3
#909IGF-1R antibody and its use for the diagnosis of cancer
#910ANTIBODIES THAT BIND CELL SURFACE GRP78 AND THEIR USE FOR DETECTION OF CANCER
#911ANTI-CD22 ANTIBODIES
#912Anti-CD303 monoclonal antibodies
#913Anti-ANG2 antibody
#914Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
#915Antibody-SN-38 immunoconjugates with a CL2A linker
#916IMMUNOCONJUGATES FOR SPECIFIC INDUCTION OF T CELL CYTOTOXICITY AGAINST A TARGET CELL
#917Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
#918ANTI-TIM3 ANTIBODIES AND METHODS OF USE
#919Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides
#920HER3 specific monoclonal antibodies for diagnostic and therapeutic use
#921Cell line overexpressing human CD303 antigen
#922METHODS OF TREATING MENINGIOMA
#923Blood brain barrier transport molecules and uses thereof
#924NOVEL ANTIBODY-ALBUMIN-DRUG CONJUGATES (AADC) AND METHODS FOR USING THEM
#925Targeted therapeutic proteins
#926Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
#927Anti-human interleukin-1 receptor accessory protein antibody and its use for treating cancer
#928Anti-CLL-1 antibodies and immunoconjugates
#929Anti-CLL-1 antibodies and immunoconjugates
#930Antibody-mediated transduction of heat shock proteins into living cells
#931Monovalent antigen binding proteins
#932Methods of delivering DLL3 antibody drug conjugates
#933Methods of making DLL3 antibody drug conjugates
#934Anti-ErbB3 antibodies and uses thereof
#935SIRP alpha-antibody fusion proteins
#936GLYCOOPTIMIZED ANTIBODY DRUG CONJUGATES
#937METHODS AND COMPOSITIONS FOR TREATMENT OF FORBES-CORI DISEASE
#938Anti-CEACAM5 antibodies and uses thereof
#939Monoclonal antibodies against HER2 epitope
#940Bispecific binding proteins and uses thereof
#941Antisense conjugates for decreasing expression of DMPK
#942Anti-DLL3 antibody drug conjugates and methods of use
#943Optimized antibodies that target CD19
#944Anti-CLL-1 antibodies and immunoconjugates
#945Phage-displayed single-chain variable fragment library
#946Cell penetrating antibodies
#947FRIZZLED 2 AS A TARGET FOR THERAPEUTIC ANTIBODIES IN THE TREATMENT OF CANCER
#948Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies
#949CD19 BINDING AGENTS AND USES THEREOF
#950BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3
#951BISPECIFIC ANTIBODIES AGAINST HER2
#952Antibodies to CD70
#953Anti SEZ6 antibodies and methods of use
#954Anti-DLL3 antibody drug conjugates
#955Anti-TIM-3 antibodies and methods of use thereof
#956Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#957Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics
#958COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR HEMATOPOIETIC ORIGIN
#959Cysteine linked nanobody dimers
#960Methods for the depletion of CD117+ cells
#961Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#962High-throughput screening of functional antibody fragments, immunoconjugate comprising the same, and adaptor-drug conjugate for screening
#963Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
#964Anti-Axl antagonistic antibodies
#965TfR selective binding compounds and related methods
#966TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR
#967Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
#968EGFRvIII antibody and composition comprising same
#969ANTIBODY-DRUG CONJUGATE OF AN ANTI-GLYPICAN-3 ANTIBODY AND A TUBULYSIN ANALOG, PREPARATION AND USES
#970CROSSLINKING OF CD22 BY EPRATUZUMAB TRIGGERS BCR SIGNALING AND CASPASE-DEPENDENT APOPTOSIS IN HEMATOPOIETIC CANCER CELLS
#971Anti-MFI2 antibodies and methods of use
#972Anti-NTB-A antibodies and related compositions and methods
#973Nucleic acid encoding bone marrow stromal antigen 1 antibody
#974Antibodies that specifically bind to TIM3
#975MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF
#976Kits containing DLL3 antibody drug conjugates
#977Anti-HER3 antibodies and uses of same
#978Antibody therapeutics that bind STAT3
#979GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE
#980Prostate-specific membrane antigen binding proteins and related compositions and methods
#981Bispecific antibodies against CD3EPSILON and ROR1
#982Binding molecules, especially antibodies, binding to L1CAM (CD171)
#983GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS
#984COMPOSITIONS AND METHODS FOR TREATING CANCER
#985Bispecific HER2 antibodies
#986Antibody binding to neuropilin 1 and use thereof
#987Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
#988Anti-TEM1 antibodies and uses thereof
#989Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
#990Compositions and methods to enhance the immune system
#991Anti-DLL3 antibody drug conjugates
#992Drug delivery of temozolomide for systemic based treatment of cancer
#993MOLECULES WITH ALTERED NEONATE FC RECEPTOR BINDING HAVING ENHANCED THERAPEUTIC AND DIAGNOSTIC PROPERTIES
#994CD27L antigen binding proteins
#995IGF-1R antibody and its use as addressing vehicle for the treatment of cancer
#996Anti-DLL3 antibody drug conjugates for treating cancer
#997Methods of making DLL3 antibody drug conjugates
#998Methods of delivering DLL3 antibody drug conjugates
#999Anti-DLL3 antibody drug conjugates
#1000PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER
#1001Antibodies against CD73
#1002Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies
#1003Eribulin-based antibody-drug conjugates and methods of use
#1004Process for the preparation of an antibody-rifamycin conjugate
#1005Therapeutic antibodies against ROR-1 protein and methods for use of same
#1006Method of treatment of gynecological cancer with anti-RAGE antibodies
#1007LOX and LOXL2 inhibitors and uses thereof
#1008Anti-PMEL17 antibodies and immunoconjugates
#1009Internalizing human monoclonal antibodies targeting prostate and other cancer cells
#1010Human monoclonal antibodies against CD25
#1011ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES
#1012Heterodimeric antibody Fc-containing proteins and methods for production thereof
#1013HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2
#1014Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
#1015ANTI-VEGFR ANTIBODY AND USES THEREOF
#1016Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
#1017Anti-PDGFR-beta antibodies and uses thereof
#1018Antibodies that bind human cannabinoid 1 (CB1) receptor
#1019Anti-FGFR3 antibodies and methods using same
#1020ANTI-ILT7 ANTIBODY
#1021Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
#1022Diagnostic and therapeutic tool for cancer
#1023USE OF ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE ANTIBODY FOR THE TREATMENT OF B-CELL MALIGNANCIES SYMPTOMS
#1024Cysteine engineered antibodies for site-specific conjugation
#1025Internalizing moieties
#1026Single-Arm Monovalent Antibody Constructs and Uses Thereof
#1027pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
#1028METHOD AND CONSTRUCTS FOR THE pH DEPENDENT PASSAGE OF THE BLOOD-BRAIN-BARRIER
#1029METHOD FOR TREATING BREAST CANCER
#1030BCMA Antigen binding proteins
#1031Antibody-SN-38 immunoconjugates with a CL2A linker
#1032Methods for treating cancer by administering humanized pan-HER antibody compositions
#1033Methods of treating a kit-associated cancer by administering anti-kit antibodies
#1034Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
#1035ANTI-C4.4A ANTIBODIES AND USES THEREOF
#1036Antibody fragments for detecting cancer and methods of use
#1037Antibodies binding AXL
#1038Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases
#1039Anti-huLRRC15 antibody drug conjugates and methods for their use
#1040Anti-huLRRC15 antibody drug conjugates and methods for their use
#1041Anti-DLL3 antibodies and drug conjugates for use in melanoma
#1042Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
#1043HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
#1044Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
#1045Antibodies directed against CD127
#1046Anti-CD324 monoclonal antibodies and uses thereof
#1047Humanized antibodies that bind LGR5
#1048Bispecific antibodies specific for PD1 and TIM3
#1049TEM8 ANTIBODIES AND METHODS OF USE
#1050Conjugates comprising an anti-EGFR1 antibody
#1051MEDICAMENTS, USES AND METHODS
#1052Intracellular delivery compounds
#1053Provasopressin antagonists and uses thereof
#1054USE OF ANTIBODY CONJUGATES
#1055Methods of treating cardiovascular disease with an ASGR inhibitor
#1056Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#1057CD33 binding agents
#1058Modulators and methods of use
#1059Site-specific conjugation of linker drugs to antibodies and resulting ADCs
#1060NOVEL ANTI-RNF43 ANTIBODIES AND METHODS OF USE
#1061Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
#1062Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
#1063Compositions and methods for the diagnosis and treatment of tumor
#1064Polynucleotides encoding anti-KIT antibodies
#1065Anti-EFNA4 antibody-drug conjugates
#1066Monoclonal antibodies against HER2 epitope and methods of use thereof
#1067HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF
#1068Anti-DPEP3 antibodies and methods of use
#1069Compositions and methods to enhance the immune system
#1070Recombinant IgG4 monovalent antibodies
#1071Antibody constructs for DLL3 and CD3
#1072Antibody drug conjugates
#1073Antibodies, antibody drug conjugates and methods of use
#1074Multi-functional mucosal vaccine platform
#1075Anti-DPEP3 antibodies and methods of use
#1076Humanized anti-TF-antigen antibodies
#1077Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof
#1078Anti-Siglec-15 antibodies and uses thereof
#1079Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof
#1080Small molecule conjugates for intracellular delivery of biologically active compounds
#1081Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
#1082Anti-HER3 antibody-drug conjugate
#1083NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
#1084Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
#1085Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
#1086Antibody-drug conjugates and uses thereof
#1087ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#1088Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#1089Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
#1090Antibody-drug conjugates and immunotoxins
#1091Multispecific antigen-binding molecules and uses thereof
#1092Antibody-drug conjugates and immunotoxins
#1093Anti-CD33 antibodies and immunoconjugates
#1094Anti-DLL3 antibody drug conjugates for treating cancer
#1095ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODY COMBINATIONS
#1096Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
#1097Anti-EphA2 antibodies and methods of use thereof
#1098Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
#1099Anti-CLL-1 antibodies and methods of use
#1100Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
#1101Cell lines expressing surface bound anti-idiotype antibodies against anti-CD22 antibodies and uses thereof
#1102ANTIBODY VACCINE CONJUGATES AND USES THEREFOR
#1103TLR3 BINDING AGENTS
#1104Optimized Fc variants and methods for their generation
#1105Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
#1106OPTIMIZED FC VARIANTS
#1107Anti-tissue factor monoclonal antibody
#1108Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
#1109CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT
#1110Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
#1111Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
#1112MET-BINDING AGENTS AND USES THEREOF
#1113Antibodies that bind OV064 and methods of use therefor
#1114Optimized Fc variants and methods for their generation
#1115Polynucleotides encoding anti-kit antibodies
#1116Antigen binding proteins that bind ErbB3
#1117Compositions and methods for inhibiting PDGFRbeta and VEGF-A
#1118MODULATION OF NKG2D
#1119Antibodies targeting B-cell receptor complex membrane bound IGM and uses thereof
#1120Anti-EGFRvIII antibodies and uses thereof
#1121Optimized Fc variants
#1122Antibody-SN-38 immunoconjugates with a CL2A linker
#1123Anti-TROP2 antibody-drug conjugate
#1124Engineered immunoglobulin Fc polypeptides displaying improved complement activation
#1125Antibodies
#1126Bispecific antigen-binding constructs targeting HER2
#1127Anti-claudin antibodies and methods of use
#1128Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
#1129TUMOR THERAPY BY BISPECIFIC ANTIBODY PRETARGETING
#1130SEZ6 modulators and methods of use
#1131Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#1132Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof
#1133Internalizing ErbB2 Antibodies
#1134Antibody-drug conjugate
#1135Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides
#1136Human neutralizing anti-kit antibodies and uses thereof
#1137Disease therapy by inducing immune response to Trop-2 expressing cells
#1138Antibodies reactive with B7-H3 and uses thereof
#1139Modulators and methods of use
#1140Glycans as functional cancer targets and antibodies thereto
#1141Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
#1142Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
#1143Conjugated antibodies against LY75 for the treatment of cancer
#1144ANTI-TIM3 ANTIBODIES AND METHODS OF USE
#1145Modulators and methods of use
#1146Antibody-SN-38 immunoconjugates with a CL2A linker
#1147Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies
#1148Anti-DLL3 antibody drug conjugates
#1149DELIVERY SYSTEM FOR CYTOTOXIC DRUGS BY BISPECIFIC ANTIBODY PRETARGETING
#1150Methods and compositions for generation of binding agents against cell surface antigens
#1151Anti-DLL3 antibody
#1152ANTIBODIES WITH MODIFIED AFFINITY TO FCRN THAT PROMOTE ANTIGEN CLEARANCE
#1153Compositions and methods to enhance the immune system
#1154Targeting intracellular target-binding determinants with intracellular antibodies
#1155Binding molecules specific for HER3 and uses thereof
#1156Methods for DNA-dependent targeting of a cell permeant antibody
#1157Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
#1158Antibody specific for CD22 and methods of use thereof
#1159TM4SF1 binding proteins and methods of using same
#1160IL-8 antibodies
#1161LIPOSOME ENCAPSULATED AFFINITY DRUG
#1162Fully human antibodies to BTLA
#1163Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
#1164Methods of Improving the Therapeutic Efficacy and Utility of Antibody Fragments
#1165Novel Delivery Compositions and Methods of Using Same
#1166Binding molecules specific for CD73 and uses thereof
#1167ANTIGEN BINDING PROTEINS
#1168LOX AND LOXL2 INHIBITORS AND USES THEREOF
#1169Anti-5T4 antibodies and uses thereof
#1170CELL-TARGETED MOLECULES COMPRISING AMINO-TERMINUS PROXIMAL OR AMINO-TERMINAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS
#1171NOVEL ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
#1172Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof
#1173Drug delivery of temozolomide for systemic based treatment of cancer
#1174Anti-immunoglobulin E antibodies and methods of using thereof
#1175Antibodies directed to HER-3 and uses thereof
#1176Antibodies to MUC16 and methods of use thereof
#1177Anti-FGFR3 antibodies and methods using same
#1178Human monoclonal antibodies to O8E
#1179TRPM4 channel inhibitors for stroke treatment
#1180Binding molecules specific for HER3 and uses thereof
#1181Anti-B7-H4 antibodies and immunoconjugates
#1182Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to G protein-coupled receptor 49 (GPR49)
#1183Fusion protein to target and treat acute myeloid leukemia cells
#1184Targeted therapeutic proteins
#1185COMBINATION OF A LIGAND OF HVEM AND AN IMMUNOTOXIN FOR USE IN THERAPY
#1186Antibodies against CD73
#1187RNA-CODED ANTIBODY
#1188Anti-mucin 1 binding agents and uses thereof
#1189Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
#1190Method for generating an affinity reagent library
#1191Anti-ErbB3 antibodies and uses thereof
#1192Antibody drug conjugates
#1193Tumor marker, monoclonal antibodies and methods of use thereof
#1194Antigen binding protein and its use as addressing product for the treatment of cancer
#1195ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA
#1196Antibodies to the B12-transcobalamin receptor
#1197Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
#1198Anti-PDGFR-beta antibodies and uses thereof
#1199Single domain antibodies against SOD1 and their use in medicine
#1200Antibodies or fragments thereof directed against a epitope of IsaA or IsaB